[go: up one dir, main page]

NI200700320A - Inhibidores de la actividad akt - Google Patents

Inhibidores de la actividad akt

Info

Publication number
NI200700320A
NI200700320A NI200700320A NI200700320A NI200700320A NI 200700320 A NI200700320 A NI 200700320A NI 200700320 A NI200700320 A NI 200700320A NI 200700320 A NI200700320 A NI 200700320A NI 200700320 A NI200700320 A NI 200700320A
Authority
NI
Nicaragua
Prior art keywords
akt activity
activity inhibitors
akt
stipulates
compounds
Prior art date
Application number
NI200700320A
Other languages
English (en)
Inventor
Mdonna J Armstrong
Essa H Hu
Iii Michael J Kelly
Yiwei Li
Jun Liang
Kevin John Krodzinak
Michael A Rossi
Philip E Sanderson
Jiabing Wang
Mark E Layton
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NI200700320A publication Critical patent/NI200700320A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención actual estipula compuestos de naftiridina sustituidos que inhiben actividad Akt. En particular, los compuestos descritos inhiben selectivamente una o dos de las isoformas de Akt. La invención también estipula composiciones que comprenden tales compuestos inhibidores y procedimientos para inhibir actividad Akt administrando el compuesto a un paciente en necesidad de tratamiento de cáncer.
NI200700320A 2005-06-10 2007-12-06 Inhibidores de la actividad akt NI200700320A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68972605P 2005-06-10 2005-06-10
US73418805P 2005-11-07 2005-11-07

Publications (1)

Publication Number Publication Date
NI200700320A true NI200700320A (es) 2008-06-17

Family

ID=37532789

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200700320A NI200700320A (es) 2005-06-10 2007-12-06 Inhibidores de la actividad akt

Country Status (22)

Country Link
US (1) US8008317B2 (es)
EP (1) EP1898903B8 (es)
JP (1) JP5055494B2 (es)
KR (1) KR100959771B1 (es)
AU (1) AU2006258124B8 (es)
BR (1) BRPI0611717A2 (es)
CA (1) CA2610888C (es)
CR (1) CR9580A (es)
DK (1) DK1898903T3 (es)
EC (1) ECSP077980A (es)
ES (1) ES2409168T3 (es)
HR (1) HRP20130429T1 (es)
IL (1) IL187690A (es)
MX (1) MX2007015578A (es)
NI (1) NI200700320A (es)
NO (1) NO20080150L (es)
NZ (1) NZ563423A (es)
PL (1) PL1898903T3 (es)
PT (1) PT1898903E (es)
RU (1) RU2421454C2 (es)
TW (1) TW200800166A (es)
WO (1) WO2006135627A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101217958A (zh) 2004-08-23 2008-07-09 默克公司 Akt活性抑制剂
AU2006258124B8 (en) 2005-06-10 2010-01-07 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
TW200806670A (en) 2006-04-25 2008-02-01 Merck & Co Inc Inhibitors of checkpoint kinases
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
AU2007327992A1 (en) * 2006-12-06 2008-06-12 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP2139333A4 (en) * 2007-03-28 2010-11-10 Merck Sharp & Dohme SUBSTITUTED PYRID- [3,2-E] - [1,2,4] -TRIAZOL- [4,3-C] -PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
SG185274A1 (en) 2007-07-05 2012-11-29 Array Biopharma Inc Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
PT2188291E (pt) 2007-08-14 2012-12-20 Bayer Ip Gmbh Pirimidinas bicíclicas fundidas
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2009148887A1 (en) 2008-06-03 2009-12-10 Merck & Co., Inc. Inhibitors of akt activity
JP2011522048A (ja) * 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
MX2011000477A (es) 2008-07-17 2011-03-15 Bayer Cropscience Ag Compuestos heterociclicos como pesticidas.
JP2012516847A (ja) * 2009-02-02 2012-07-26 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
BRPI1008745A2 (pt) 2009-02-05 2019-09-17 Tokai Pharmaceuticals Inc pró-fármacos de inibidores esteroidais de cyp17/antiandrogênios
CA2752105C (en) 2009-02-13 2017-10-31 Matthias Vennemann Fused pyrimidines
JP5667085B2 (ja) 2009-02-13 2015-02-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ａｋｔインヒビターとしての融合されたピリミジン
WO2010101734A1 (en) * 2009-03-06 2010-09-10 Merck Sharp & Dohme Corp. Combination cancer therapy with an akt inhibitor and other anticancer agents
WO2010104933A1 (en) * 2009-03-11 2010-09-16 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8168652B2 (en) 2009-03-12 2012-05-01 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EP2266985A1 (en) * 2009-06-26 2010-12-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Tricyclic Pyrimidine Derivatives as Wnt antagonists
EP2473495A1 (en) 2009-09-18 2012-07-11 Almac Discovery Limited Pharmaceutical compounds
US20120252806A1 (en) * 2009-12-17 2012-10-04 Kelly Iii Michael J Inhibitors of akt activity
GB0922589D0 (en) * 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
EP2593451B1 (en) * 2010-07-12 2015-08-19 Bayer Intellectual Property GmbH Substituted imidazo[1,2-a]pyrimidines and -pyridines
ES2603032T3 (es) * 2010-07-15 2017-02-23 Bayer Intellectual Property Gmbh Compuestos de 3-piridil-heteroarilcarboxamida como pesticidas
HUE026323T2 (en) 2011-04-07 2016-05-30 Bayer Ip Gmbh Imidazopyridazines as akt kinase inhibitors
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
MY169029A (en) * 2012-05-17 2019-02-04 Genentech Inc Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
AU2014208964B2 (en) 2013-01-23 2016-09-01 Astrazeneca Ab Chemical compounds
EP4066841A1 (en) 2013-03-14 2022-10-05 University of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
EP3091016A1 (en) * 2015-05-05 2016-11-09 Technische Universität Dortmund Kinase inhibitors and their use in cancer therapy
CN107056755B (zh) * 2015-12-07 2019-02-22 苏州信诺维医药科技有限公司 五元杂环酰胺类wnt通路抑制剂
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
CN111093663A (zh) 2017-09-07 2020-05-01 奥古斯塔大学研究所公司 特异性akt3激活剂及其用途
EP4073102A4 (en) 2019-12-12 2024-05-08 Ting Therapeutics LLC Compositions and methods for the prevention and treatment of hearing loss
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
WO2023081812A2 (en) * 2021-11-05 2023-05-11 Georgiamune Llc Akt3 modulators
WO2025196161A2 (en) 2024-03-20 2025-09-25 Specialty Operations France Cosmetic compositions, use thereof, and methods for using such compositions
WO2025196160A1 (en) 2024-03-20 2025-09-25 Specialty Operations France Cosmetic compositions, use thereof, and methods for using such compositions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831013A (en) * 1986-03-20 1989-05-16 Ciba-Geigy Corporation 2-substituted-e-fused-[1,2,4]triazolo[1,5-c]pyrimidines, pharmaceutical compositions, and uses thereof
CA2223624C (en) * 1995-06-06 2001-02-20 Pfizer Inc. Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-.alpha.]pyridines
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
GB9824897D0 (en) * 1998-11-12 1999-01-06 Merck Sharp & Dohme Therapeutic compounds
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
CA2442270C (en) 2001-04-10 2009-09-08 Merck & Co., Inc. Inhibitors of akt activity
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2003226271B2 (en) 2002-04-08 2007-10-18 Merck Sharp & Dohme Corp. Fused quinoxaline derivatives as inhibitors of Akt activity
CA2480880C (en) 2002-04-08 2011-03-22 Merck & Co., Inc. Inhibitors of akt activity
EP1494675A4 (en) 2002-04-08 2006-07-19 Merck & Co Inc HEMMER OF ACT ACTIVITY
CA2480800C (en) * 2002-04-08 2008-09-23 Mark T. Bilodeau Inhibitors of akt activity
EP1539754A4 (en) * 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOCHINOLINONE AND ITS USE
ATE503483T1 (de) 2002-10-30 2011-04-15 Merck Sharp & Dohme Hemmer der akt aktivität
AU2004233826B2 (en) 2003-04-24 2009-08-13 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
AU2004233828B2 (en) * 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CA2522430A1 (en) * 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
WO2004096135A2 (en) * 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
CN1863779B (zh) 2003-10-15 2010-05-05 宇部兴产株式会社 吲唑衍生物
US7750151B2 (en) 2004-04-09 2010-07-06 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CN101217958A (zh) 2004-08-23 2008-07-09 默克公司 Akt活性抑制剂
CA2588474A1 (en) 2004-12-02 2006-06-29 Merck & Co., Inc. Inhibitors of akt activity
EP1827436A4 (en) 2004-12-15 2011-08-10 Merck Sharp & Dohme INHIBITORS OF ACT ACTIVITY
CN101115479A (zh) 2005-02-14 2008-01-30 默克公司 Akt活性抑制剂
CA2602197A1 (en) 2005-04-12 2006-10-19 Merck & Co., Inc. Inhibitors of akt activity
AU2006258124B8 (en) 2005-06-10 2010-01-07 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt

Also Published As

Publication number Publication date
EP1898903B1 (en) 2013-03-27
KR20080016627A (ko) 2008-02-21
AU2006258124A1 (en) 2006-12-21
TW200800166A (en) 2008-01-01
EP1898903A4 (en) 2010-07-21
NZ563423A (en) 2010-05-28
HRP20130429T1 (en) 2013-06-30
IL187690A (en) 2012-06-28
ES2409168T3 (es) 2013-06-25
NO20080150L (no) 2008-03-10
RU2008100045A (ru) 2009-07-20
IL187690A0 (en) 2008-11-03
WO2006135627A2 (en) 2006-12-21
RU2421454C2 (ru) 2011-06-20
MX2007015578A (es) 2008-03-06
CA2610888C (en) 2011-02-08
US20100222321A1 (en) 2010-09-02
BRPI0611717A2 (pt) 2009-01-13
CA2610888A1 (en) 2006-12-21
EP1898903B8 (en) 2013-05-15
DK1898903T3 (da) 2013-07-01
AU2006258124B2 (en) 2009-09-03
JP2009501698A (ja) 2009-01-22
AU2006258124B8 (en) 2010-01-07
KR100959771B1 (ko) 2010-05-28
PT1898903E (pt) 2013-06-28
EP1898903A2 (en) 2008-03-19
US8008317B2 (en) 2011-08-30
WO2006135627A3 (en) 2008-07-31
CR9580A (es) 2008-09-23
JP5055494B2 (ja) 2012-10-24
ECSP077980A (es) 2008-01-23
PL1898903T3 (pl) 2013-08-30

Similar Documents

Publication Publication Date Title
NI200700320A (es) Inhibidores de la actividad akt
ECSP099376A (es) Inhibidores de la actividad de la akt
WO2006091395A3 (en) Inhibitors of akt activity
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
EA200900227A1 (ru) Пептидомиметики smac, применимые в качестве ингибиторов iap (ингибитор белков апоптоза)
ECSP067080A (es) DIFENILIMIDAZOPIRIMIDINA Y AMINAS IMIDAZOL COMO INHIBIDORES DE ß-SECRETASA
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
CR20140544A (es) Compuestos para inhibir la progresión mitotica
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
MX2009003405A (es) Composiciones farmaceuticas de inhibidores de la histona desacetilasa y compuestos quelantes de metal, y complejos de quelato de metal-inhibidor de histona desacetilasa.
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
MX379353B (es) Compuesto de piperidina tipo quinoxalina sustituida y uso de los mismos.
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
WO2006110638A3 (en) Inhibitors of akt activity
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
WO2007059154A3 (en) Treatment of cancers with acquired resistance to kit inhibitors
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
AR111697A2 (es) Composición oftálmica para el tratamiento de las alergias oculares
ECSP078015A (es) 4-anilino-3-quinolinocarbonitrilos para el tratamiento de cáncer
WO2007008502A3 (en) Inhibitors of checkpoint kinases
WO2007084135A3 (en) Inhibitors of checkpoint kinases